Propanc Biopharma, Inc. Share Price

Equities

PPCB

US74346N6022

Pharmaceuticals

Market Closed - OTC Markets 01:26:51 27/04/2024 am IST 5-day change 1st Jan Change
0.001 USD -9.09% Intraday chart for Propanc Biopharma, Inc. -9.09% -91.67%
Sales 2022 - Sales 2023 - Capitalization 559K 46.57M
Net income 2022 -2M -167M Net income 2023 -2M -167M EV / Sales 2022 -
Net Debt 2022 1.09M 91.24M Net Debt 2023 536K 44.68M EV / Sales 2023 -
P/E ratio 2022
-0.07 x
P/E ratio 2023
-0.08 x
Employees 2
Yield 2022 *
-
Yield 2023
-
Free-Float 97.69%
More Fundamentals * Assessed data
Dynamic Chart
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding CI
More news
1 day-9.09%
1 week-9.09%
Current month-68.75%
1 month-74.36%
3 months-81.48%
6 months-91.60%
Current year-91.67%
More quotes
1 week
0.00
Extreme 0.00095
0.00
1 month
0.00
Extreme 0.00095
0.00
Current year
0.00
Extreme 0.00095
0.02
1 year
0.00
Extreme 0.00095
0.40
3 years
0.00
Extreme 0.00095
240.00
5 years
0.00
Extreme 0.00095
1 000 000.00
10 years
0.00
Extreme 0.00095
1 000 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 15/07/15
Founder 77 15/07/15
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 50 15/07/15
Founder 77 15/07/15
Director/Board Member 74 23/20/23
More insiders
Date Price Change Volume
26/24/26 0.001 -9.09% 3,347,792
25/24/25 0.0011 +4.76% 1,676,690
24/24/24 0.00105 -12.50% 1,446,200
23/24/23 0.0012 +9.09% 1,610,545
22/24/22 0.0011 0.00% 12,454,791

Delayed Quote OTC Markets, April 27, 2024 at 01:26 am IST

More quotes
Propanc Biopharma, Inc. is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on the development of cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development.
More about the company